Navigation Links
Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe
Date:12/3/2009

e information will be quality checked for potential presentation at a scientific or medical conference or meeting in the first half of 2010.
  • Introduction of MuGard into several additional countries in Europe is anticipated over the next 12 to 18 months.
  • "As of today, more than 2,000 cancer patients undergoing radiotherapy and/or chemotherapy have been treated with MuGard," stated Jean-Francois Labbe, SpePharm's President & CEO. "We are very pleased with progress to date, and MuGard is well accepted by patients and by healthcare professionals, both as a preventative and curative treatment. MuGard's ready-to-use formulation helps to support treatment compliance by the patients, and we believe is leading to its adoption as treatment-of-choice to prevent and treat oral mucositis."

    "Access is pleased with the early acceptance of MuGard as a preventative and curative treatment for oral mucositis," stated Jeffrey Davis, Access' President & CEO. "We hope to be able to leverage SpePharm's early experiences around its launch in Europe to jump start our efforts here throughout the remainder of the year and into 2010."

    MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop oral mucositis. The market for the prevention and treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patient
    '/>"/>

    SOURCE Access Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Investor Relations Firm Access IR/PR and The Communications Strategy Group Announce Strategic Alliance
    2. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
    3. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
    4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
    5. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
    6. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
    7. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
    8. Access Pharmaceuticals CEO Interviewed on Financial Website
    9. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
    10. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
    11. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
    (Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
    (Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
    (Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
    Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... California, August 20 IsoTis, Inc.,(NASDAQ: ISOT ) ... letter dated August 15, 2007 from the US Food ... for,marketing in the US as Class II medical devices. ... Accell Connexus and,Accell Total Bone Matrix, as well as ...
    ... Thermo Fisher,Scientific Inc. (NYSE: TMO ) announced ... president and chief executive,officer, are adopting stock- trading ... covering the future sale of company stock. Mr.,Dekkers, ... over August,15-17, 2007, has adopted a plan for ...
    ... awarded Malaysia,s Darjah Yang Mulia Pangkuan Negeri -, ... (TSX: GEN),a company focused on developing simple blood-based ... personalized health management, today,announced that its co-founder and ... Darjah Yang Mulia Pangkuan Negeri (DMPN), a State ...
    Cached Biology Technology:IsoTis Receives FDA Clearance for Accell Family of Products 2IsoTis Receives FDA Clearance for Accell Family of Products 3IsoTis Receives FDA Clearance for Accell Family of Products 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2
    (Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
    (Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
    (Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
    Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
    ... today presents a map of normal human genetic variation ... alterations in our chromosomes. In a DNA version of ,spot-the-difference, ... healthy people from Europe, the Americas and East Asia, systematically ... published in Nature , open new approaches for research ...
    ... the potential to revolutionize the biological understanding of some ... a single protein involved in brain development, called "SRGAP3," ... of mice that cause symptoms that are similar to ... this protein has similar functions in humans, it may ...
    ... women with breast cancer who do not respond or have ... used alongside traditional chemotherapy and radiotherapy blocks the female ... the tumour to grow; it has been shown to improve ... about one third of patients with the appropriate type of ...
    Cached Biology News:Spot the difference 2Single protein targeted as the root biological cause of several childhood psychiatric disorders 2Scientists unravel resistance to breast cancer treatment 2
    ...
    p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
    Goat polyclonal to Duffy / FY / DARC...
    Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
    Biology Products: